Results 221 to 230 of about 1,279,892 (312)

Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense   +4 more
wiley   +1 more source

TRIM Expression and Its Association With Disease Activity in Systemic Lupus Erythematosus

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse manifestations, including rash, arthritis, and nephritis. Although autoantibodies are a key feature of SLE, their levels often poorly reflect disease severity, suggesting the involvement of additional contributing factors.
Ling‐Ying Lu   +8 more
wiley   +1 more source

Frequency and factors associated with flare-ups in lupus patients with lupus nephritis in French Guiana. [PDF]

open access: yesFront Nephrol
Makembi Bunkete A   +10 more
europepmc   +1 more source

Allogeneic Human Bone Marrow‐Derived Mesenchymal Stem Cells Accelerate Diabetic Wound Healing via Inflammation Suppression and Angiogenesis Promotion: A Preclinical Study

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Mesenchymal stem cells (MSCs) have been shown to enhance tissue regeneration and wound healing. This preclinical study investigated the therapeutic potential of human bone marrow‐derived mesenchymal stem cells (hBM‐MSCs) for accelerating diabetic wound healing.
Rong‐Fu Chen   +5 more
wiley   +1 more source

Long‐Term Outcomes of the Anterior Ethmoidal Artery Flap for Nasal Septal Perforation Repair

open access: yesThe Laryngoscope, EarlyView.
While NSP closure success was 90% at 6 months postoperatively, success dropped to about 70% at final follow‐ups, with a majority of failures occurring after 1 year postoperatively. Patients most often achieved long‐term symptomatic relief and were happy they had undergone NSP repair.
John R. Craig   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy